Skip to main content
    M

    Madrigal Pharmaceuticals Inc (MDGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $423.96
    -3.43 (-0.80%)

    Market Cap: $9.93B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Madrigal Pharmaceuticals Inc (MDGL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Madrigal Pharmaceuticals are Mirum Pharmaceuticals (MIRM), BridgeBio Pharma (BBIO) and Protagonist Therapeutics (PTGX). By market cap, Madrigal Pharmaceuticals ranks 4th of the 13 companies on this page; BridgeBio Pharma (BBIO) is the largest at $15.25B. The median P/E of the 4 companies with a P/E is 53.4x.

    Peer Comparison

    MDGL's ROIC of -12.7% is above the peer median of -36.5%, and its revenue growth of 50.1% is below the median of 50.2%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Madrigal Pharmaceuticals (MDGL)$9.93BN/A8.7x-10.9%-12.7%50.1%0.00%
    Mirum Pharmaceuticals Inc (MIRM)$6.14BN/A8.9x-134.7%-133.6%39.6%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Ligand Pharmaceuticals Incorporated (LGND)$6.18B66.5x23.7x20.3%0.1%-31.8%0.00%
    Rhythm Pharmaceuticals Inc (RYTM)$7.97BN/A26.4x-69.0%-98.6%79.6%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Disc Medicine Inc. (IRON)$3.64BN/AN/A0.0%-40.0%0.0%0.00%
    Kymera Therapeutics Inc (KYMR)$10.89BN/A123.2x0.0%N/A466.4%0.00%
    Peer median$9.11B53.4x17.4x0.0%-36.5%50.2%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Madrigal Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Mirum Pharmaceuticals Inc (MIRM)
    Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies...
    MIRM competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Ligand Pharmaceuticals Incorporated (LGND)
    Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover...
    LGND competitors
    Rhythm Pharmaceuticals Inc (RYTM)
    Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment...
    RYTM competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    Disc Medicine Inc. (IRON)
    Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development...
    IRON competitors
    Kymera Therapeutics Inc (KYMR)
    Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down...
    KYMR competitors

    Frequently Asked Questions About MDGL

    Who are Madrigal Pharmaceuticals' main competitors?

    The companies most similar to Madrigal Pharmaceuticals include Mirum Pharmaceuticals (MIRM), BridgeBio Pharma (BBIO), Protagonist Therapeutics (PTGX), Praxis Precision Medicines (PRAX) and Krystal Biotech (KRYS), listed from the closest match.

    Who is Madrigal Pharmaceuticals' biggest competitor?

    BridgeBio Pharma (BBIO) is the largest of the similar companies at $15.25B; Mirum Pharmaceuticals (MIRM) is the closest match by business profile, size, sector and industry.

    How does MDGL stock compare with its competitors?

    MDGL's P/S is 8.7x against a peer median of 17.4x; its net margin is -10.9% against a peer median of 0.0%.

    Which of Madrigal Pharmaceuticals' competitors pays a higher dividend?

    Madrigal Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Madrigal Pharmaceuticals bigger than its competitors?

    No. Madrigal Pharmaceuticals is 4th by market cap among the 13 companies on this page; the largest is BridgeBio Pharma (BBIO) at $15.25B.